Takeda Strengthens Berlin Site as Future German Headquarters

Takeda, a leading global pharmaceutical company, has announced its decision to move the headquarters of Takeda GmbH – its German subsidiary – from Constance to Berlin by the end of 2028. Berlin already serves as a central hub for key commercial operations in Germany. With this move, Takeda is reinforcing its presence in the capital and will concentrate its activities on three strategic locations: Berlin, Oranienburg, and Singen. The state-of-the-art manufacturing sites in Singen and Oranienburg will remain integral pillars of the organisation, underscoring Germany’s importance as a key industrial base for Takeda.

Takeda strengthens Berlin as its future headquarters in Germany

“Relocating our corporate headquarters to Berlin is a clear commitment to Germany, Takeda’s fourth-largest market,” said Dr Ingeborg R. Borgheim, Managing Director of Takeda in Germany. “We are strengthening our footprint in Berlin alongside our two global manufacturing sites in Singen (Baden-Württemberg) and Oranienburg (Brandenburg).”

Timeline until 2028

The relocation is expected to be completed by the end of 2028. The Constance site, which historically served as the headquarters of Takeda GmbH and Takeda Germany, will be closed by year-end 2028. Approximately 60 employees based in Constance have been informed of the plans.

Transparency for employees

“We recognise that this represents a significant change for our colleagues in Constance,” said Michael Hartmann, Managing Director of Human Resources and Labour Relations at Takeda Germany. “With today’s announcement, we are ensuring early and transparent communication. We are currently in discussions with the works council.”

Strong signal for Germany

With 2,300 employees in Germany, two global manufacturing sites, and the future national headquarters in Berlin, Takeda is sending a strong signal of its long-term commitment to Germany.

About Takeda

Takeda is committed to improving people’s health and creating a brighter future for the world. Our mission is to discover and deliver life-transforming treatments in our core therapeutic and business areas, including Gastroenterology and Inflammatory Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Neuroscience, and Vaccines. Through partnerships, we aim to enhance patients’ quality of life and advance new treatment options through our dynamic and diverse pipeline. As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we are guided by our dedication to patients, our people, and the planet. These values, which have defined Takeda for over two centuries, inspire our teams in nearly 80 countries and regions.
More information: https://www.takeda.com


For further information about the growth industries, economic development, business and technology support for companies, investors and scientific institutions in the Airport Region Berlin Brandenburg please contact:

Sandra Koletzki ​​​​​​ | sandra.koletzki(at)airport-region.de

(Source: Takeda Pharma Vertrieb GmbH & Co. KG, 07|24|2025 | "TTakeda Strengthens Berlin Site as Future German Headquarters")